TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. - Wikidata - awgldk - TriplyDB

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

http://www.wikidata.org/entity/Q37623535

about

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.

P2860

Q33943277-8C53E730-771E-4A3B-BB7F-55481E70C18E Q34289202-434C5F09-1796-4181-B76A-C2CF677F86F1 Q34993145-032289A8-12C1-4200-9170-3EFC5F1E0FDE Q35750567-E43786C0-C5E6-451A-A37F-501037B84F17 Q36205970-2A551D5D-3D4E-40C7-80FA-0BF0CCAD7593 Q36989582-F4B3308B-C10A-4432-A558-28B727593C7E Q38721796-27352CFC-181F-44E7-AB95-FA0A4D90E27D Q47782376-C2828E67-F5CA-460A-B375-5D69E5DDBFE1 Q48282223-3ED16389-9A87-4193-9189-CA1C0A782865

P2860

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

http://www.wikidata.org/entity/Q37623535

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

TTT-3002 is a novel FLT3 tyros ...... eukemias in vitro and in vivo.

@en

TTT-3002 is a novel FLT3 tyros ...... eukemias in vitro and in vivo.

@nl

type

label

TTT-3002 is a novel FLT3 tyros ...... eukemias in vitro and in vivo.

@en

TTT-3002 is a novel FLT3 tyros ...... eukemias in vitro and in vivo.

@nl

prefLabel

TTT-3002 is a novel FLT3 tyros ...... eukemias in vitro and in vivo.

@en

TTT-3002 is a novel FLT3 tyros ...... eukemias in vitro and in vivo.

@nl

P1433

Q37623535-4B5771EA-896E-4F29-B86B-89B864A2A27A

P1476

Q37623535-713E7228-09E2-4430-B8C7-144BCB26B495

P2093

Q37623535-2255DA46-CE54-4303-A20F-4DE35DE19B1A

Q37623535-341AA8EB-7151-4AF4-BCD4-CA0AED1EFD35

Q37623535-4DD16D3E-D1C6-403B-877F-A5E37D27E36E

Q37623535-6A05083E-51F4-4651-9F54-2E96049BFF58

Q37623535-A84B7FCA-BAF8-4148-B12C-DAA018DBA22B

Q37623535-BB1164AE-E721-4CD1-8420-DDA75EA0BEE2

Q37623535-BBBFADC1-2175-481A-82C2-61CFB3D994BB

Q37623535-C8F297B2-22AC-4D3F-A3BA-9475277A0AF1

Q37623535-DE38895C-3E3D-4AD0-9075-459CBDFB80C4

Q37623535-F2EFF0C9-3FD8-4853-BD69-47DDF302E8E0

P2860

Q37623535-02FDBBA9-0045-4A94-87A5-D182A2F76F0C

Q37623535-048116BD-BD28-4F88-9A47-5861BFE6526F

Q37623535-189917C6-F37C-46E8-B5C7-07C4D801ED66

Q37623535-1A664BF3-DB45-4078-BACD-C2CD3851F6D6

Q37623535-1F7905C2-D370-43FB-8EB8-8E908872C1C5

Q37623535-22010258-9189-4AEA-9A07-BE2DF8C0765B

Q37623535-23E767A4-ABE2-4AE8-8538-D9F32F1E833E

Q37623535-26B57FDE-881C-4121-B790-983CAC41CC1F

Q37623535-3BBDE87A-2F4E-41FE-9E7B-92BEE8F263E3

Q37623535-3FDC6ACB-3147-4B6B-AC0D-E07B2406794F

P304

Q37623535-18F34F88-AE9A-474B-B13F-59A9AC284A5D

P31

Q37623535-3BC63E4F-3A89-4236-9330-BA6800642F3A

P356

Q37623535-C0F8A0AD-B3A9-45D7-AD3C-D8F1CE018915

P407

Q37623535-2E327809-3057-4D03-96EC-1625733EB946

P433

Q37623535-BF9F8D68-1D3B-4E59-A5CC-09FE92F628BD

P478

Q37623535-8FA7EC8D-0F7E-4A91-BEFB-9530A348D886

P577

Q37623535-903BB753-08E6-4DA4-A163-BA7C2AA143C9

P5875

Q37623535-1013F004-BD37-40DE-9F86-1B2267BBE18E

P698

Q37623535-D31AD30E-68A4-49F9-A7F3-68FAC84EE56D

P921

Q37623535-A5318948-2D0B-4449-A67D-997016568BCA

P932

Q37623535-E31058A3-C13C-4C78-9951-96C0B33F90C4

P356

BLOOD-2013-08-523035

P1433

P1476

TTT-3002 is a novel FLT3 tyros ...... eukemias in vitro and in vivo.

@en

P2093

Allen Williams

http://www.w3.org/2001/XMLSchema#string

Amy Duffield

http://www.w3.org/2001/XMLSchema#string

Bao Nguyen

http://www.w3.org/2001/XMLSchema#string

Donald Small

http://www.w3.org/2001/XMLSchema#string

Hayley Ma

http://www.w3.org/2001/XMLSchema#string

Li Li

http://www.w3.org/2001/XMLSchema#string

Mark Levis

http://www.w3.org/2001/XMLSchema#string

Michelle Rudek

http://www.w3.org/2001/XMLSchema#string

Ming Zhao

http://www.w3.org/2001/XMLSchema#string

Sarah Greenblatt

http://www.w3.org/2001/XMLSchema#string

P2860

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice

Antitumor activity of sorafenib in FLT3-driven leukemic cells.

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

P304

1525-1534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-08-523035

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259652545

http://www.w3.org/2001/XMLSchema#string

P698

24408321

http://www.w3.org/2001/XMLSchema#string

P921

P932

3945863

http://www.w3.org/2001/XMLSchema#string